Delivery Order HHSN261201500041I-HHSN26100003
Award Date
9/1/16
Potential Completion Date
8/31/18
Potential Value
$712K
Federal Agency
National Cancer Institute
Awardee
Sri International
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
West Menlo Park, CA 94025, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $509,357.00, was issued by the National Cancer Institute (NCI) to SRI International, a non-profit research and development organization. The contract, titled "OVARIAN CANCER CHEMOPREVENTION (SHETA2)," is part of the NCI's Preclinical Prevention Cancer Program and is focused on preclinical efficacy and intermediate endpoint biomarkers related to ovarian cancer. The period of performance runs from September 24, 2015 to September 23, 2017, with a...
This is a federal contract award from the National Cancer Institute, a civilian agency within the Department of Health and Human Services, to SRI International, a non-profit research and development institute. The contract, worth $21,593,775.02, is for "PRECLINICAL PHARMACOLOGICAL STUDIES OF ANTITUMOR AND OTHER THERAPEUTIC AGENTS" and was awarded on December 15, 2004 with a completion date of December 14, 2012. The contract type is Definitive Contract with a Cost Plus Fixed Fee pricing...
This is a $7,910,623.00 cost-plus-fixed-fee contract awarded by the National Cancer Institute (part of the U.S. Department of Health and Human Services) to SRI International, a non-profit research and development institute. The contract is for analysis of anti-cancer chemicals and pharmaceutical formulations. It does not have a small business set-aside designation. SRI International frequently serves as a prime contractor and subcontractor on research and development contracts and grants with...
This is a $67,787,765.29 cost-plus-fixed-fee contract awarded by the National Cancer Institute (NCI) to SRI International, a non-profit research and development institute, for preclinical toxicology and pharmacology of drugs. The contract supports biomedical research and drug development services for the NCI. SRI International has multiple indefinite delivery vehicles (IDVs) with federal agencies like the Department of Defense, NASA, and the National Institutes of Health that enable efficient...
This is a Cost Plus Fixed Fee delivery order with a ceiling value of $212,246.94 awarded by the National Cancer Institute (NCI) to Sri International, a large non-profit research institute. The task order is for a tissue cross-reactivity study of a human antibody called CBAB1, which is being developed as a potential anti-cancer therapy. This order is part of the NCI's larger Toxicology of Drugs Developed for Cancer Patients contract vehicle. Sri International has significant experience conducting...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $287,312.00 cost-plus-fixed-fee delivery order contract to Sri International, a non-profit research institute, for a "Tissue Cross-Reactivity Study of a Human Antibody." This contract is under the parent "Toxicology of Drugs Developed for Cancer Patients" indefinite delivery vehicle (IDV). Sri International has a history of providing research, development, and...
This federal contract award is for an "OTHER FUNCTIONS - CONTRACT ORIENTATION MEETING WITH NCI, OFFICE OF ACQUISITIONS" valued at $4,144.00. The award was made by the National Cancer Institute (NCI), which is part of the U.S. Department of Health and Human Services, to the prime contractor Sri International, a non-profit research and development institute. The contract is a Delivery Order under the Preclinical Efficacy and Intermediate Endpoint Biomarkers contract vehicle. Sri...
This is a federal contract awarded by the National Cancer Institute, a component of the Department of Health and Human Services, to SRI International, a non-profit research and development institute. The contract is for the synthesis of non-GMP (non-Good Manufacturing Practice) small molecules, with a total ceiling value of $5,499,854.59. The contract type is Cost Plus Fixed Fee, and the ultimate completion date is June 30, 2012. SRI International has a history of supporting federal agencies...
This is a $7,905,977.22 cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to SRI International, a non-profit research and development institute. The contract supports RADIATION/NUCLEAR MEDICAL COUNTERMEASURE (MCM) PRODUCT DEVELOPMENT SERVICES, specifically for animal model development and initial efficacy testing of candidate MCMs. The contract has a...
This is a $547,860 delivery order contract awarded by the National Cancer Institute (NCI) of the Department of Health and Human Services (HHS) to The Institute for Cancer Research, a non-profit research organization. The contract is part of the Preclinical Efficacy and Intermediate Endpoint Biomarkers indefinite delivery vehicle, which supports the PREVENT Cancer Preclinical Drug Development Program. Under this 5-year IDIQ, The Institute for Cancer Research provides preclinical efficacy...